

Abteilung "Neurologie"

Journalbeiträge

1. Adams HA, Baumann G, Cascorbi I, Ebener C, Emmel M, Geiger S, Jansens U, Klima U, Klippe HJ, Knoefel WT, Marx G, Müller-Werdan U, Pape HC, Piek J, Prange H, Roesner D, Roth B, Schürholz T, Standl T, Teske W, Vogt PM, Werner GS, Windolf J, Zander R, Zerkowski HR (2005) Empfehlungen zur Diagnostik und Therapie der Schockformen der IAG Schock der DIVI. Teil 2: hypovolämischer Schock. *Intensivmed u Notfallmed*, 42: 96-109.
2. Adams HA, Baumann G, Cascorbi I, Ebener C, Emmel M, Geiger S, Jansens U, Klima U, Klippe HJ, Knoefel WT, Marx G, Müller-Werdan U, Pape HC, Piek J, Prange H, Roesner D, Roth B, Schürholz T, Standl T, Teske W, Vogt PM, Werner GS, Windolf J, Zander R, Zerkowski HR (2005) Empfehlungen zur Diagnostik und Therapie der Schockformen der IAG Schock der DIVI. Teil 4: Anaphylaktischer Schock. *Intensivmed u Notfallmed*, 42: 299-304.
3. Adams HA, Baumann G, Cascorbi I, Ebener C, Emmel M, Geiger S, Jansens U, Klima U, Klippe HJ, Knoefel WT, Marx G, Müller-Werdan U, Pape HC, Piek J, Prange H, Roesner D, Roth B, Schürholz T, Standl T, Teske W, Vogt PM, Werner GS, Windolf J, Zander R, Zerkowski HR (2005) Empfehlungen zur Diagnostik und Therapie der Schockformen der IAG Schock der DIVI. Teil 6: Neurogener Schock. *Intensivmed u Notfallmed*, 42: 615-619.
4. Adams HA, Baumann G, Cascorbi I, Ebener C, Emmel M, Geiger S, Jansens U, Klima U, Klippe HJ, Knoefel WT, Marx G, Müller-Werdan U, Pape HC, Piek J, Prange H, Roesner D, Roth B, Schürholz T, Standl T, Teske W, Vogt PM, Werner GS, Windolf J, Zander R, Zerkowski HR (2005) Empfehlungen zur Diagnostik und Therapie der Schockformen der IAG Schock der DIVI. Teil 5: Septischer Schock. *Intensivmed u Notfallmed*, 42: 531-543.
5. Adams HA, Baumann G, Cascorbi I, Ebener C, Emmel M, Geiger S, Jansens U, Klima U, Klippe J, Knoefel WT, Marx G, Müller-Werdan U, Pape HC, Piek J, Prange H, Roesner D, Roth B, Schürholz T, Standl T, Teske W, Vogt PM, Werner GS, Windolf J, Zander R, Zerkowski HR (2005) Empfehlungen zur Diagnostik und Therapie der Schockformen der IAG Schock der DIVI. Teil 3: Kardialer Schock. *Intensivmed u Notfallmed*, 42: 196-210.
6. Banares S, Zeh K, Krajewska M, Kermer P, Baribault H, Reed JC, Krajewski S (2005) Novel pan-neuronal Cre-transgenic line for conditional ablation of genes in the nervous system. *GENESIS*, 42(1): 6-16.
7. Bartels E, Henning S, Wellmer A, Giraldo-Velásquez M, Kermer P (2005) Evaluation of cerebral perfusion deficit in stroke patients using new transcranial contrast imaging CPS technology--preliminary results. *ULTRASCHALL MED*, 26(6): 478-86.
8. Bleich S, Otto M, Zerr I, Kropp S, Kretzschmar HA, Wiltfang J (2005) Creutzfeldt-Jakob disease and homocysteine levels in plasma and cerebrospinal fluid. *GERONTOLOGY*, 51(2): 142-4.
9. Blumel J, Burger R, Gerlich W, Gurtler L, Heiden M, Hitzler W, Jansen B, Klamm H, Ludwig WD, Montag-Lessing T, Offergeld R, Paessens A, Pauli G, Seitz R, Schlenkrich U, Schottstedt V, Willkommen H, Beekes M, Zerr I (2005) Variant Creutzfeldt-Jacob Disease. *TRANSFUS MED HEMOTH*, 32: 227-236.
10. Boesenberg C, Schulz-Schaeffer WJ, Meissner B, Kallenberg K, Bartl M, Heinemann U, Krasnianski A, Stoeck K, Varges D, Windl O, Kretzschmar HA, Zerr I (2005) Clinical course in young patients with sporadic Creutzfeldt-Jakob disease. *ANN NEUROL*, 58(4): 533-43.
11. Cepek L, Steinacker P, Mollenhauer B, Wiese B, Ciesielczyk B, Bibl M, Wiltfang J, Zerr I, Schulz-Schaeffer W, Kretzschmar HA, Poser S, Otto M (2005) Follow-up investigations of tau protein and S-100B levels in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. *DEMENT GERIATR COGN*, 19(5-6): 376-82.
12. Czéh B, Simon M, Schmelting B, Hiemke C, Fuchs E (2005) Astroglial Plasticity in the Hippocampus is Affected by Chronic Psychosocial Stress and Concomitant Fluoxetine Treatment. *NEUROPSYCHOPHARMACOL*, -: -.
13. Diem R, Sättler MB, Merkler D, Demmer I, Maier K, Stadelmann C, Ehrenreich H, Bähr M (2005) Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. *BRAIN*, 128(Pt 2): 375-85.
14. Diem R, Taheri N, Dietz GP, Kuhnert A, Maier K, Sättler MB, Gadjanski I, Merkler D, Bähr M (2005) HIV-Tat-mediated Bcl-XL delivery protects retinal ganglion cells during experimental autoimmune optic neuritis. *NEUROBIOL DIS*, 20(2): 218-26.
15. Diem R, Sättler B, Maier K, Bähr M (2005) Molecular mechanisms of neuronal apoptosis in chronic inflammatory CNS disease. *Signal transduction*, 5: 250-255.
16. Diem R, Sättler MB, Bähr M (2005) Neurodegeneration im Rahmen chronisch entzündlicher ZNS-Erkrankungen: Mechanismen und Ansätze für neuroprotektive Therapien. *Neuroforum*, 3: 88-94.
17. Dietz GP, Bähr M (2005) Peptide-enhanced cellular internalization of proteins in neuroscience. *BRAIN RES BULL*, 68(1-2): 103-14.
18. Dietz GP, Schott M, Labes M, Bähr M (2005) Expression of the protein inhibitor of nitric oxide synthase in the adult rat retina before and after optic nerve lesion. *MOL BRAIN RES*, 136(1-2): 118-24.

Abteilung "Neurologie"

19. Djukic M, Böttcher T, Wellmer A, Gerber J, Brocke VV, Eiffert H, Nau R (2005) Moxifloxacin in experimental *Streptococcus pneumoniae* cerebritis and meningitis. *NEUROCRIT CARE*, 2(3): 325-9.
20. Döhlinger S, Humpe A, Connor J, Köhler M, Legler TJ (2005) Flow-cytometric screening of platelet antibodies with previously frozen cells. *J IMMUNOL METHODS*, 297(1-2): 169-75.
21. Ebert S, Dietz GP, Mitchell TJ, Michel U, Bähr M, Nau R (2005) Limited protection of TAT-Bcl-X(L) against pneumolysin-induced neuronal cell death. *NEUROSCI LETT*, 384(3): 349-53.
22. Ebert S, Gerber J, Bader S, Mühlhauser F, Brechtel K, Mitchell TJ, Nau R (2005) Dose-dependent activation of microglial cells by Toll-like receptor agonists alone and in combination. *J NEUROIMMUNOL*, 159(1-2): 87-96.
23. Engelhorn T, Doerfler A, Weise J, Baehr M, Forsting M, Hufnagel A (2005) Cerebral perfusion alterations during the acute phase of experimental generalized status epilepticus: prediction of survival by using perfusion-weighted MR imaging and histopathology. *AM J NEURORADIOL*, 26(6): 1563-70.
24. Fuchs E (2005) Social stress in tree shrews as an animal model of depression: an example of a behavioral model of a CNS disorder. *CNS SPECTRUMS*, 10(3): 182-90.
25. Fuchs E, Czeh B, Flügge G (2005) Preclinical approaches to examine novel concepts of the pathophysiology of depressive disorders: lessons learned from the tree shrews. *DRUG DEVELOP RES*, 65(4): 309-317.
26. Fuchs E, Flügge G (2005) Depressionen: Eine Störung der Neuroplastizität. *Psychoneuro*, 31: 197-203.
27. Gerber J, Lotz M, Ebert S, Kiel S, Huether G, Kuhnt U, Nau R (2005) Melatonin is neuroprotective in experimental *Streptococcus pneumoniae* meningitis. *J INFECT DIS*, 191(5): 783-90.
28. Gold R, Stadelmann C, Linker R, Diem R, Bähr M, Brück W (2005) Neue Erkenntnisse zur Pathogenese der multiplen Sklerose. *Dtsch Ärztebl*, 102(17): 1204-1210.
29. Hofstetter HH, Mössner R, Lesch KP, Linker RA, Toyka KV, Gold R (2005) Absence of reuptake of serotonin influences susceptibility to clinical autoimmune disease and neuroantigen-specific interferon-gamma production in mouse EAE. *CLIN EXP IMMUNOL*, 142(1): 39-44.
30. Jacobi C, Arlt S, Reiber H, Westner I, Kretschmar HA, Poser S, Zerr I (2005) Immunoglobulins and virus-specific antibodies in patients with Creutzfeldt-Jakob disease. *ACTA NEUROL SCAND*, 111(3): 185-90.
31. Kermer P, Bähr M (2005) [Programmed cell death in the retina Molekulare Mechanismen and therapeutic strategies.]. *OPHTHALMOLOGE*, 102(7): 674-8.
32. Kovács GG, Puopolo M, Ladogana A, Pocchiari M, Budka H, van Duijn C, Collins SJ, Boyd A, Giulivi A, Coulthart M, Delasnerie-Laupretre N, Brandel JP, Zerr I, Kretschmar HA, de Pedro-Cuesta J, Calero-Lara M, Glatzel M, Aguzzi A, Bishop M, Knight R, Belay G, Will R, Mitrova E (2005) Genetic prion disease: the EURO-CJD experience. *HUM GENET*, 118(2): 166-74.
33. Krasnianski A, Deschauer M, Neudecker S, Gellerich FN, Müller T, Schoser BG, Krasnianski M, Zierz S (2005) Mitochondrial changes in skeletal muscle in amyotrophic lateral sclerosis and other neurogenic atrophies. *BRAIN*, 128(Pt 8): 1870-6.
34. Krebs B, Lederer RM, Windl O, Grasbon-Frodl EM, Zerr I, Kretschmar HA (2005) Creutzfeldt-Jakob disease associated with an R148H mutation of the prion protein gene. *NEUROGENETICS*, 6(2): 97-100.
35. Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, Klug GM, Sutcliffe T, Giulivi A, Alperovitch A, Delasnerie-Laupretre N, Brandel JP, Poser S, Kretschmar H, Rietveld I, Mitrova E, Cuesta Jde P, Martinez-Martin P, Glatzel M, Aguzzi A, Knight R, Ward H, Pocchiari M, van Duijn CM, Will RG, Zerr I (2005) Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. *NEUROLOGY*, 64(9): 1586-91.
36. Liman J, Ganesan S, Dohm CP, Krajewski S, Reed JC, Bähr M, Wouters FS, Kermer P (2005) Interaction of BAG1 and Hsp70 mediates neuroprotectivity and increases chaperone activity. *MOL CELL BIOL*, 25(9): 3715-25.
37. Lingor P, Koeberle P, Kügler S, Bähr M (2005) Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced retinal ganglion cell death in vivo. *BRAIN*, 128(Pt 3): 550-8.
38. Lingor P, Schöll U, Bähr M, Kügler S (2005) Functional applications of novel Semliki Forest virus vectors are limited by vector toxicity in cultures of primary neurons in vitro and in the substantia nigra in vivo. *EXP BRAIN RES*, 161(3): 335-42.
39. Linker RA, Reinhardt M, Bendszus M, Ladewig G, Briel A, Schirner M, Mäurer M, Hauff P (2005) In vivo molecular imaging of adhesion molecules in experimental autoimmune encephalomyelitis (EAE). *J AUTOIMMUN*, 25(3): 199-205.
40. Linker RA, Rott E, Hofstetter HH, Hanke T, Toyka KV, Gold R (2005) EAE in beta-2 microglobulin-deficient mice: axonal damage is not dependent on MHC-I restricted immune responses. *NEUROBIOL DIS*, 19(1-2): 218-28.
41. Linker RA, Sendtner M, Gold R (2005) Mechanisms of axonal degeneration in EAE--lessons from CNTF and MHC I knockout mice. *J NEUROL SCI*, 233(1-2): 167-72.

Abteilung "Neurologie"

42. Linker RA, Stadelmann C, Diem R, Bähr M, Brück W, Gold R (2005) [Recent advances in pathogenesis and therapy of multiple sclerosis]. *FORTSCHR NEUROL PSYC*, 73(12): 715-27.
43. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, Heine H, Penke B, Neumann H, Fassbender K (2005) LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. *BRAIN*, 128(8): 1778-9.
44. Lotz M, Ebert S, Esselmann H, Iliev AI, Prinz M, Wiazewicz N, Wiltfang J, Gerber J, Nau R (2005) Amyloid beta peptide 1-40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. *J NEUROCHEM*, 94(2): 289-98.
45. Malik JM, Shevtsova Z, Bähr M, Kügler S (2005) Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer. *MOL THER*, 11(3): 373-81.
46. Mattie Dagger H, Stuertz K, Nau R, van Dissel JT (2005) Pharmacodynamics of antibiotics with respect to bacterial killing of and release of lipoteichoic acid by *Streptococcus pneumoniae*. *J ANTIMICROB CHEMOTH*, 56(1): 154-9 Epub 2005 May 26.
47. Meier A, Mollenhauer B, Cohrs S, Rodenbeck A, Jordan W, Meller J, Otto M (2005) Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease. *BRAIN RES*, 1063(2): 201-3.
48. Meissner B, Westner IM, Kallenberg K, Krasnianski A, Bartl M, Varges D, Bösenberg C, Kretzschmar HA, Knauth M, Schulz-Schaeffer WJ, Zerr I (2005) Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. *NEUROLOGY*, 65(10): 1544-50.
49. Michel U, Malik I, Ebert S, Bähr M, Kügler S (2005) Long-term in vivo and in vitro AAV-2-mediated RNA interference in rat retinal ganglion cells and cultured primary neurons. *BIOCHEM BIOPH RES CO*, 326(2): 307-12.
50. Mollenhauer B, Bibl M, Trenkwalder C, Stiens G, Cepek L, Steinacker P, Ciesielczyk B, Neubert K, Wiltfang J, Kretzschmar HA, Poser S, Otto M (2005) Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. *J NEURAL TRANSM*, 112(7): 933-48.
51. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, Neumann M, Steinacker P, Kretzschmar HA, Poser S, Trenkwalder C, Otto M (2005) Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. *DEMENT GERIATR COGN*, 19(2-3): 164-70.
52. Nau R, Eiffert H (2005) Minimizing the release of proinflammatory and toxic bacterial products within the host: a promising approach to improve outcome in life-threatening infections. *FEMS IMMUNOL MED MIC*, 44(1): 1-16.
53. Ouyang Y, Wong M, Capani F, Rensing N, Lee CS, Liu Q, Neusch C, Martone ME, Wu JY, Yamada K, Ellisman MH, Choi DW (2005) Transient decrease in F-actin may be necessary for translocation of proteins into dendritic spines. *EUR J NEUROSCI*, 22(12): 2995-3005.
54. Pizzi M, Sarnico I, Boroni F, Benarese M, Steimberg N, Mazzoleni G, Dietz GP, Bähr M, Liou HC, Spano PF (2005) NF-kappaB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. *CELL DEATH DIFFER*, 12(7): 761-72.
55. Pracht D, Elm C, Gerber J, Bergmann S, Rohde M, Seiler M, Kim KS, Jenkinson HF, Nau R, Hammerschmidt S (2005) PavA of *Streptococcus pneumoniae* modulates adherence, invasion, and meningeal inflammation. *INFECT IMMUN*, 73(5): 2680-9.
56. Reinhardt M, Hauff P, Linker RA, Briel A, Gold R, Rieckmann P, Becker G, Toyka KV, Mürer M, Schirner M (2005) Ultrasound derived imaging and quantification of cell adhesion molecules in experimental autoimmune encephalomyelitis (EAE) by Sensitive Particle Acoustic Quantification (SPAQ). *NEUROIMAGE*, 27(2): 267-78.
57. Roeber S, Krebs B, Neumann M, Windl O, Zerr I, Grasbon-Frodl EM, Kretzschmar HA (2005) Creutzfeldt-Jakob disease in a patient with an R208H mutation of the prion protein gene (PRNP) and a 17-kDa prion protein fragment. *ACTA NEUROPATHOL*, 109(4): 443-8.
58. Rostasy K, Withut E, Pohl D, Lange P, Ciesielczyk B, Diem R, Gärtner J, Otto M (2005) Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis. *J CHILD NEUROL*, 20(10): 822-5.
59. Rygula R, Abumaria N, Flügge G, Fuchs E, Rüter E, Havemann-Reinecke U (2005) Anhedonia and motivational deficits in rats: impact of chronic social stress. *BEHAV BRAIN RES*, 162(1): 127-34.
60. Sättler MB, Diem R, Merkle D, Demmer I, Boger I, Stadelmann C, Bähr M (2005) Simvastatin treatment does not protect retinal ganglion cells from degeneration in a rat model of autoimmune optic neuritis. *EXP NEUROL*, 193(1): 163-71.
61. Schaller BJ, Bahr M, Buchfelder M (2005) Pathophysiology of brain ischemia: penumbra, gene expression, and future therapeutic options. *EUR NEUROL*, 54(4): 179-80.
62. Schneider-Gold C, Gajdos P, Toyka K, Hohlfeld R (2005) Corticosteroids for myasthenia gravis. *Cochrane Library* (Internet-Ausgabe), (2): CD002828.

Abteilung "Neurologie"

63. Schneider-Gold C, Bahr M, Gold R (2005) Mycophenolate mofetil: A new therapeutic option in neuroimmunological diseases. *AKTUEL NEUROL*, 32(8): 477-80.
64. Schöfer H, Brockmeyer NH, Hagedorn HJ, Hamouda O, Handrick W, Krause W, Marcus U, Münstermann D, Petry KU, Prange H, Potthoff A, Gross G (2005) Syphilis. Guideline of the DSTDG on diagnosis and therapy. *HAUTARZT*, 56(11): 1084.
65. Schuchhardt V, Prange H (2005) Tuberkulöse Meningitis. *Intensivmed u Notfallmed*, 42(1): 9-15.
66. Shevtsova Z, Malik JM, Michel U, Bähr M, Kügler S (2005) Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. *EXP PHYSIOL*, 90(1): 53-9.
67. Simon M, Czéh B, Fuchs E (2005) Age-dependent susceptibility of adult hippocampal cell proliferation to chronic psychosocial stress. *BRAIN RES*, 1049(2): 244-8.
68. Steinacker P, Schwarz P, Reim K, Brechlin P, Jahn O, Kratzin H, Aitken A, Wiltfang J, Aguzzi A, Bahn E, Baxter HC, Brose N, Otto M (2005) Unchanged survival rates of 14-3-3gamma knockout mice after inoculation with pathological prion protein. *MOL CELL BIOL*, 25(4): 1339-46.
69. Stoeck K, Bodemer M, Ciesielczyk B, Meissner B, Bartl M, Heinemann U, Zerr I (2005) Interleukin 4 and interleukin 10 levels are elevated in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. *ARCH NEUROL-CHICAGO*, 62(10): 1591-4.
70. Strik H, Luthe H, Nagel I, Ehrlich B, Bahr M (2005) Automated cerebrospinal fluid cytology: limitations and reasonable applications. *ANAL QUANT CYTOL*, 27(3): 167-73.
71. Strik HM, Borchert H, Fels C, Knauth M, Rienhoff O, Bähr M, Verhey JF (2005) Three-dimensional reconstruction and volumetry of intracranial haemorrhage and its mass effect. *NEURORADIOLOGY*, 1: 1-12.
72. Tauber SC, Stadelmann C, Spreer A, Brück W, Nau R, Gerber J (2005) Increased expression of BDNF and proliferation of dentate granule cells after bacterial meningitis. *J NEUROPATH EXP NEUR*, 64(9): 806-15.
73. Tschampa HJ, Kallenberg K, Urbach H, Meissner B, Nicolay C, Kretzschmar HA, Knauth M, Zerr I (2005) MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. *BRAIN*, 128(9): 2026-33 Epub 2005 Jun 15.
74. Vigo T, Nobbio L, Hummelen PV, Abbruzzese M, Mancardi G, Verpoorten N, Verhoeven K, Sereda MW, Nave KA, Timmerman V, Schenone A (2005) Experimental Charcot-Marie-Tooth type 1A: a cDNA microarrays analysis. *MOL CELL NEUROSCI*, 28(4): 703-14.
75. Weise J, Engelhorn T, Dörfler A, Aker S, Bähr M, Hufnagel A (2005) Expression time course and spatial distribution of activated caspase-3 after experimental status epilepticus: contribution of delayed neuronal cell death to seizure-induced neuronal injury. *NEUROBIOL DIS*, 18(3): 582-90.
76. Weishaupt JH, Klöcker N, Bähr M (2005) Axotomy-induced early down-regulation of POU-IV class transcription factors Brn-3a and Brn-3b in retinal ganglion cells. *J MOL NEUROSCI*, 26(1): 17-25.
77. Wiltfang J, Lewczuk P, Riederer P, Grünblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselmann H, Henkel AW, Kornhuber J, Blennow K (2005) Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. *WORLD J BIOL PSYCHIA*, 6(2): 69-84.
78. Xiang W, Windl O, Westner IM, Neumann M, Zerr I, Lederer RM, Kretzschmar HA (2005) Cerebral gene expression profiles in sporadic Creutzfeldt-Jakob disease. *ANN NEUROL*, 58(2): 242-57.

Buchbeiträge

1. Adams HA, Baumann G, Cascorbi I, Ebener C, Emmel M, Geiger S, Jansens U, Klima U, Klippe HJ, Knoefel WT, Marx G, Müller-Werdan U, Pape HC, Piek J, Prange H, Roesner D, Roth B, Schürholz T, Standl T, Teske W, Vogt PM, Werner GS, Windolf J, Zander R, Zerkowski HR (2005) Pathophysiologie und Therapie des hypovolämischen Schocks. In: Deutsche Akademie für Anästhesiologische Fortbildung (Hg.) Refresher Course - Aktuelles Wissen für Anästhesisten. DIOMed Verlags GmbH, Ebelsbach, 1-20.
2. Diem R, Bähr M (2005) Evidence for Neuronal Apoptosis in Demyelinating CNS Diseases. In: Waxman S (Hg.) Multiple Sclerosis as a Neuronal Disease. Academic Press, Elsevier Science, USA, 327-339.
3. Nau R, Behnke-Mursch J, Eiffert H, Piek J, Pfister HW (2005) Hirnabszess. In: Diener HC, Putzki N, Berlit P (Hg.) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme Verlag, Stuttgart, 352-358.
4. Pfister HW, Eiffert H, Müller M, Nau R (2005) Bakterielle (eitrig) Meningoenzephalitis. In: Diener HC, Putzki N, Berlit P (Hg.) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme Verlag, Stuttgart, 322-330.
5. Poser S, Zerr I (2005) Möglichkeiten und Bedeutung neurobiochemischer Diagnostik. In: Wallesch CW (Hg.) Neurologie - Diagnostik und Therapie in Klinik und Praxis. Urban & Fischer Verlag, München, 117-125.

Abteilung "Neurologie"

6. Prange H, Hagedorn HJ, Ritter G, Schuchardt V, Weller M (2005) Neurosyphilis. In: Diener HC, Putzki N, Berlit P (Hg.) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme Verlag, Stuttgart, 376-382.
7. Prange H, Krone B, Meyding-Lamade U, Schmutzhardt E, Schuchardt V (2005) Virale Meningoenzephalitis. In: Diener HC, Putzki N, Berlit P (Hg.) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme Verlag, Stuttgart, 331-342.
8. Prange H, Meyding-Lamade U, Schmutzhardt E (2005) Atypische erregerbedingte Meningoenzephalitiden. In: Diener HC, Putzki N, Berlit P (Hg.) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme Verlag, Stuttgart, 342-5.
9. Schneider-Gold C, Meinck HM, Lehmann-Horn F (2005) Myotone Dystrophien und nichtdystrophe Myotonien. In: Diener HC, Putzki N, Berlit P (Hg.) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme Verlag, Stuttgart, 555-564.
10. Zerr I, Janzen RWC, Schulz JB, Steinhoff BJ, Urbach H (2005) Creutzfeldt-Jakob-Krankheit. In: Diener HC, Putzki N, Berlit P (Hg.) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme Verlag, Stuttgart, 317-321.

Medizinische Dissertationen

1. Bartl M, Dr. med., Die Creutzfeldt-Jakob-Krankheit bei älteren Patienten. Dissertation Universität Göttingen 2005.
2. Fischer A, Dr. med., Effects of internal and external factors on adult hippocampal neurogenesis in the rat brain. Dissertation Universität Göttingen 2005.
3. Giovanopoulos A, Dr. med., Erreger Bakterieller Meningitiden - Einfluss des pH-Wertes auf die Ergebnisse der in-vitro-Empfindlichkeitsprüfung. Dissertation Universität Göttingen 2005.
4. Henckel K, Dr. med., Experimentelle Untersuchungen zur kombinierten Wirkung von Interferon-beta (IFN- β) und ??-Strahlen auf Kolonkarzinomzellen in vitro. Dissertation Universität Göttingen 2005.
5. Heyer A, Dr. med., Untersuchungen zum hypoxieinduzierten Zelltod in primären hippocampalen Neuronen der Ratte - Geschlechtsunterschiede und protektiver Einfluss von 17 β -Östradiol. Dissertation Universität Göttingen 2005.
6. Kämmer D, Dr. med., Experimentelles Neurotrauma im Mausmodell: Neuroprotektive Therapie in Verhaltensbiologie, Histologie und Bildgebung. Dissertation Universität Göttingen 2005.
7. Kemmling-Keric´ Y, Dr. med., Die Rolle des S-100B-Proteins in der Frühphase zerebraler Ischämien. Dissertation Universität Göttingen 2005.
8. Köhler A, Dr. med., Untersuchung von Liquor- und Serummarkern zur Früherkennung von Patienten mit axonal/neuronal betonter Verlaufsform der Multiplen Sklerose. Dissertation Universität Göttingen 2005.
9. Körtner K, Dr. med., Die Demenz bei der sporadischen Creutzfeldt-Jakob-Krankheit - Probleme der Diagnostik und vorherrschende Symptomatik. Dissertation Universität Göttingen 2005.
10. Ohlander C, Dr. med., Sinus- und Venenthrombosen des Gehirns bei Erwachsenen - Eine katamnestiche Studie von 47 konsekutiven Krankheitsfällen (Vorgeschichte, Lokalisation, Verlauf, Therapieergebnis). Dissertation Universität Göttingen 2005.
11. Pohl K, Dr. med., Freisetzung von Lipoteichonsäuren und Teichonsäuren aus Streptococcus pneumoniae Typ 3 während der Behandlung mit Protein- und Nukleinsäuresynthese-hemmenden Antibiotika. Dissertation Universität Göttingen 2005.
12. Zirk A, Dr. med., Das Acinuszellkarzinom der großen Kopfspeicheldrüsen - Eine retrospektive Analyse von 36 Fällen. Dissertation Universität Göttingen 2005.